证券日报网讯 10月31日晚间，诺思格发布公告称，公司股票于2025年10月29日、2025年10月30日、 2025年10月31日连续三个交易日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情况。经 核实，公司前期披露的信息不存在需要更正、补充之处；公司未发现近期公共传媒报道了可能或已经对 本公司股票交易价格产生较大影响的未公开重大信息；近期公司经营情况及内外部经营环境未发生重大 变化。 （编辑 任世碧） ...

南财智讯10月31日电，诺思格公告，公司股票于2025年10月29日、2025年10月30日、2025年10月31日连 续三个交易日收盘价格涨幅偏离值累计超过30%，根据深圳证券交易所交易规则的相关规定，属于股票 交易异常波动的情况。针对上述情况，公司董事会对公司、控股股东及实际控制人进行了核实，确认公 司前期披露的信息不存在需要更正或补充之处；近期公共传媒未有对本公司股票交易价格产生较大影响 的未公开重大信息；公司经营情况及内外部环境未发生重大变化；公司、控股股东和实际控制人不存在 应披露而未披露的重大事项，或处于筹划阶段的重大事项；在股票交易异常波动期间，控股股东和实际 控制人未买卖公司股票。公司董事会确认，目前没有任何应予以披露而未披露的事项，也未获悉任何对 本公司股票及其衍生品种交易价格产生较大影响的信息。公司提醒投资者注意风险，理性投资。 ...

Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

一、股票交易异常波动的具体情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"） 股票于 2025 年 10 月 29 日、2025 年 10 月 30 日、2025 年 10 月 31 日连续三个交易日收盘价 格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》的相关规定，属 于股票交易异常波动的情况。 二、说明关注、核实情况 证券代码：301333 证券简称：诺思格 公告编号：2025-049 诺思格（北京）医药科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所创业板股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格 产生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 针对公司股票交易异常波动情况，公司董事会对公司、控 ...

证券代码：301333 证券简称：诺思格 公告编号：2025-048 诺思格（北京）医药科技股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、持有人会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）2025年员工持 股计划第一次持有人会议（以下简称"本次会议"）于2025年10月31日在公司会 议室以现场结合通讯方式召开。本次会议由董事会秘书李树奇先生主持。出席本 次会议的持有人共35人，代表2025年员工持股计划份额1,499.9904万份，占公司 2025年员工持股计划已认购总份额的100%。会议的召集、召开和表决程序符合 相关法律法规、规范性文件及公司《2025年员工持股计划（草案）》《2025年员工 持股计划管理办法》的规定。 二、持有人会议审议情况 表决结果：同意 1,499.9904 万份，占出席持有人会议的持有人所持份额总数 的 100%，反对 0 份，弃权 0 份。 为保证员工持股计划的顺利进行，保障持有人的合法权益，根据公司《2025 年员工持股计划管理办法》 ...

Core Viewpoint - The company reported steady revenue growth and exceeded profit expectations in Q3 2025, driven by a low base from the previous year and a higher number of project settlements [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 607 million, a year-on-year increase of 8.09%, and a net profit attributable to shareholders of 96 million, up 13.21%. The net profit after deducting non-recurring items was 81 million, reflecting a growth of 22.47% [1]. - In Q3 2025 alone, the company recorded revenue of 228 million, representing a year-on-year growth of 24.48%. The net profit attributable to shareholders was 34 million, up 32.98%, while the net profit after deducting non-recurring items reached 30 million, marking a significant increase of 52.69% [2]. - The gross profit margin for the first three quarters was 35.61%, down 3.58 percentage points year-on-year, while the net profit margin increased by 0.65 percentage points to 15.94%. Management and sales expense ratios improved, with management expenses at 10.07% (down 5.11 percentage points) and sales expenses at 1.66% (down 0.24 percentage points) [2]. Industry Outlook - The onset of a rate-cutting cycle by the Federal Reserve, with a 25 basis point cut in September 2025 and expectations for further cuts, is anticipated to gradually revive investment and financing, benefiting the clinical CRO sector [3]. - The introduction of domestic innovative drug support policies is expected to favor local clinical CROs, positioning the company for rapid growth opportunities [3]. Profit Forecast and Investment Recommendation - Revenue projections for 2025-2027 are estimated at 776 million, 852 million, and 969 million, with year-on-year growth rates of 4.33%, 9.75%, and 13.79%, respectively. Net profit attributable to shareholders is forecasted at 150 million, 163 million, and 181 million, with growth rates of 6.85%, 8.83%, and 11.26% [3]. - The company is assigned a "buy" rating with corresponding price-to-earnings ratios of 33, 31, and 28 for the years 2025, 2026, and 2027 [3].

Core Viewpoint - Norsg achieved a daily limit increase of 20.00%, with a turnover rate of 16.62% and a transaction volume of 558 million yuan, indicating strong market interest and activity in the stock [2] Trading Activity - Institutional investors net bought 66.92 million yuan, while brokerage seats collectively net sold 28.46 million yuan on the same day [2] - The top five trading departments accounted for a total transaction volume of 147 million yuan, with a net buying amount of 38.46 million yuan [2] - Specific institutional buying included amounts of 27.01 million yuan, 20.58 million yuan, 19.03 million yuan, and 12.40 million yuan from various specialized seats [2] Fund Flow - The stock saw a net inflow of 66.37 million yuan from major funds, with a significant inflow of 74.26 million yuan from large orders, while smaller orders experienced a net outflow of 7.89 million yuan [2] - Over the past five days, the net inflow of major funds totaled 74.31 million yuan, indicating a positive trend in investor sentiment [2]

Core Points - The Shanghai Composite Index closed at 4016.33 points, above the six-month moving average, with an increase of 0.70% [1] - The total trading volume of A-shares reached 22,906.74 billion yuan [1] - A total of 145 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Notable stocks with high deviation rates include: - Digital Human: 20.14% deviation, closing price of 18.47 yuan, with a daily increase of 29.98% and a turnover rate of 26.73% [1] - Weston: 19.60% deviation, closing price of 61.52 yuan, with a daily increase of 19.99% and a turnover rate of 48.37% [1] - Norsg: 19.43% deviation, closing price of 61.92 yuan, with a daily increase of 20.00% and a turnover rate of 16.62% [1] Other Stocks - Stocks with smaller deviation rates that just crossed the six-month line include: - Vatti: minimal deviation, closing price of 7.99 yuan, with a daily increase of 7.97% [1] - ST Huake: minimal deviation, closing price of 6.19 yuan, with a daily increase of 6.17% [1] - Lisheng Pharmaceutical: minimal deviation, closing price of 6.51 yuan, with a daily increase of 11.09% [1]

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301315 | 威士顿 | 19.99 | 47.99 | 51.44 | 61.52 | 19.60 | | 301333 | 诺思格 | 20.00 | 15.54 | 51.85 | 61.92 | 19.43 | | 000034 | 神州数 码 | 7.88 | 13.55 | 40.39 | 43.54 | 7.79 | | 002391 | 长青股 份 | 9.97 | 10.62 | 6.04 | 6.51 | 7.77 | | 688223 | 晶科能 源 | 7.01 | 1.78 | 5.43 | 5.80 | 6.82 | | 000007 | 全新好 | 7.57 | 4.70 | 7.46 | 7.96 | 6.76 | | 920670 | 数字人 | 15.20 | 16.90 | 15.36 | 16.37 | ...

创新药概念股午后持续拉升，诺思格20cm涨停，普蕊斯、康芝药业涨超10%，泰格医药、康龙化成、 贝达药业涨幅居前。 ...